Citadel Advisors
MANE

Citadel Advisors’s Veradermics Inc MANE Stock Holding History

Citadel Advisors’s Portfolio MANE Stock Details MANE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231M Buy
1,877,775
+52,103
+3% +$4.88M 0.03% 490
2026
Q1 		$115M Buy
+1,825,672
New +$92.1M 0.02% 724

Other funds holding MANE

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors's MANE Position: Q2 2026 in Review

Citadel Advisors increased its Veradermics Inc (MANE) stake by 2.9% in Q2 2026, buying an estimated $4.88M and bringing the position to 1,877,775 shares worth $231M. The position accounts for 0.03% of the portfolio, ranked #490.

Citadel Advisors first reported a position in MANE in Q1 2026 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold MANE as of Q2 2026.

  • Citadel Advisors held 1,877,775 shares of Veradermics Inc worth $231M as of Q2 2026.
  • Citadel Advisors bought 52,103 Veradermics Inc shares in Q2 2026, an estimated $4.88M.
  • Veradermics Inc made up 0.03% of Citadel Advisors's portfolio in Q2 2026, its #490 holding.
  • Citadel Advisors first reported a position in Veradermics Inc in Q1 2026 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Veradermics Inc as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.